Small-molecule scaffold-based peptidomimetics with ultrashort peptide fragments achieved MICs ≤8 μg/mL against pathogenic bacteria, retaining full activity against drug-resistant E. coli with acceptable safety profiles.
≤8 μg/mL MICPeptidomimetics achieved potent concentrations against both sensitive and drug-resistant bacteria
What the researchers found
Several scaffold-based peptidomimetics achieved MICs ≤8 μg/mL (~3 μM) against pathogenic bacteria, with full activity retained against drug-resistant E. coli and a bactericidal mechanism confirmed at 2× MIC.
Why it matters
These scaffold-based peptidomimetics bridge the gap between natural AMPs (effective but unstable) and small-molecule drugs (stable but increasingly resisted), offering a new compound class for the antibiotic resistance crisis.
How the study worked
Synthesis of peptidomimetics using bis-, tris-, and tetrakis(bromomethyl)benzene and triamine scaffolds; MIC testing against Gram-positive and Gram-negative panel; drug-resistant E. coli testing; hemolysis and cell viability assays.
What this study cannot tell us
In vitro activity only. In vivo efficacy, pharmacokinetics, and toxicity not assessed. Limited to a few scaffold types. Safety window needs optimization for some compounds.
How to read the evidence
In vitro drug discovery study with activity against a relevant bacterial panel including resistant strains. Early-stage requiring in vivo validation.
When this study was published
Published in 2025.
The bigger picture
Peptidomimetics represent a middle ground between natural AMPs and conventional antibiotics — combining the resistance-evading properties of peptides with the drug-like properties of small molecules.
Questions still open
- Can the most potent compounds be optimized for in vivo use?
- How do these peptidomimetics affect beneficial gut bacteria?
- Could scaffold diversity be expanded to improve activity spectrum?
Common questions
What are peptidomimetics?
Do they work against resistant bacteria?
Read the original research
Antibacterial peptidomimetics via fragment display on small-molecule scaffolds.
RSC medicinal chemistry
Citation
Dyhr, Emma; Cañete de Pinedo, Lucía; Frederiksen, Nicki; Bojer, Martin Saxtorph; Ingmer, Hanne; Sæbø, Ingvill Pedersen; Ræder, Synnøve Brandt; Bjørås, Magnar; Helgesen, Emily; Booth, James Alexander; Franzyk, Henrik. (2026). Antibacterial peptidomimetics via fragment display on small-molecule scaffolds.. RSC medicinal chemistry. https://doi.org/10.1039/d5md00916b